132 results about "Calcitonin" patented technology

A compound, as shown in Formula I, is a multi-heterocyclic compound. It has been verified that the compound provided by this invention integrates a novel compound targeting the calcitonin gene-related peptide (CGRP) based on ephedrine. Upon contact with the skin, due to photoactivated cell biological function regulation and the blocking effect of the multi-heterocyclic compound I structure on serotonin receptors, it achieves therapeutic effects on cutaneous vascular malformations and telangiectasia, improves the effectiveness of phototherapy in improving chronic cutaneous vascular diseases, and promotes skin wound healing.

The invention discloses an abdominal aortic aneurysm progress prediction method and system based on cross-modal knowledge distillation. The method comprises the following steps: collecting blood of a target object; the method comprises the following steps: detecting the concentration of blood protein fingerprint markers of blood of a target object, wherein the blood protein fingerprint markers comprise matrix metalloproteinase-12, calcitonin-related polypeptide-alpha, uromodulin, nerve injury induction protein-1, glycosylated hemoglobin A1c and fibroblast growth factor-9; carrying out abdominal aortic aneurysm risk calculation by calling Student-net of cross-modal knowledge distillation based on the blood protein fingerprint marker concentration; wherein the input of the Teaser-net of the cross-modal knowledge distillation comprises a CTA image feature and a pathological section feature, and a category probability vector output by the Student-net is aligned with a category probability vector output by the Teaser-net; and outputting the risk level of the abdominal aortic aneurysm and the probability of occurrence / progress / rupture of the abdominal aortic aneurysm in the preset year. And the development of the aortic aneurysm disease is accurately predicted.

The present disclosure provides compounds for modulating calcitonin receptor and / or amylin receptor activity, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating a calcitonin receptor and / or amylin receptor associated disease or disorder.

The present disclosure provides compounds for modulating calcitonin receptor and / or amylin receptor activity, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating a calcitonin receptor and / or amylin receptor associated disease or disorder.

The present disclosure provides compounds for modulating calcitonin receptor and / or amylin receptor activity, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating a calcitonin receptor and / or amylin receptor associated disease or disorder.

The inventors discovered that calcitonin gene-related peptide (CGRP) inhibitors reduce pain caused by bone fracture without impeding healing of the fracture. Accordingly, disclosed herein are methods for treating pain in a subject that has sustained a bone fracture, and the methods comprise administering a therapeutically effective amount of a CGRP inhibitor to the subject.

The invention relates to a sepsis detection system which evaluates the sepsis risk of a patient in real time by integrating clinical signs, various physiological parameters, laboratory detection data and biomarkers and utilizing an intelligent algorithm. The system comprises a data acquisition module, a data transmission module, a data processing module, a user display module and an alarm module. The data acquisition module monitors physiological parameters such as consciousness, body temperature, heart rate, respiratory rate, finger pulse oxygen saturation, invasive blood pressure, urine volume and skin piebald in real time, and biomarker data such as leukocyte count, neutrophile granulocyte, neutrophile granulocyte number, C-reactive protein, procalcitonin and interleukin-6 are obtained through blood detection. And the data processing module performs sepsis risk assessment by integrating the biomarkers and the physiological parameters in combination with a machine learning model, and outputs a risk level. The user display module displays the evaluation result in real time and provides treatment suggestions, and the alarm module triggers an alarm under the high-risk condition to ensure timely intervention.

The present invention provides a stable calcitonin calibrator and a preparation method thereof, belonging to the technical field of calibrator preparation. The calibrator comprises the following components: a buffer, a salt substance, a sugar substance, a polyol substance, a preservative, a protein substance, a composite protective agent and calcitonin; the composite protective agent is obtained by mixing sodium caseinate, sodium hydroxypropyl methylcellulose and sodium carboxymethyl cellulose in a mass ratio of 2:1:1. The calcitonin calibrator of the present invention has a validity period of up to 36 months, can be stable for 1 year under the condition of ‑20°C after re-dissolution, can be stable for 3 months under the condition of 2‑8°C after re-dissolution, and can be stable for 1 month under the condition of room temperature after re-dissolution, providing a stable and good-performance calibrator for calcitonin diagnostic reagents.

The present invention relates to a process for preparing the compound of Formula I in the form of a base or a salt thereof, and its use as an intermediate for the preparation of calcitonin gene- related peptide (CGRP) receptor antagonist active pharmaceutical ingredients, in particular zavegepant, where the compound of Formula I is the following: (I)

Nausea and vomiting are unpleasant events caused by a variety of triggering factors. Wherein medicines often cause nausea and vomiting. An anti-tumor chemotherapeutic agent is one of the most emetic drugs, and often causes chemotherapy-induced nausea and vomiting (CINV). The latter seriously impairs the therapeutic effect and the quality of life of the patient. It is of great interest in determining agents capable of preventing and combating drug-induced nausea and vomiting, including CINV. A calcitonin gene-related peptide (CGRP) is a neuropeptide having various effects in a human body. However, neuropeptide effects in the brain are still to be clarified. CGRP receptor antagonists (named as gezepam) have been recently approved for use in the treatment of migraine. The use of gezepams for the direct treatment of nausea and vomiting, including CINV, is described.

The application discloses a kind of light illumination methods for laying hens in later egg production stage.The method comprises: in the breeding process of laying hens in later egg production stage, using light source to emit blue light illumination or blue light and white light illumination to irradiate laying hens, so that the illumination can improve eggshell quality.The method of the application can up-regulate the expression of CaBP-D28k gene in eggshell gland of laying hens in later production stage, improve the ability of eggshell calcium deposition, regulate the secretion of parathyroid hormone PTH, calcitonin CT and other hormones, maintain the balance of blood calcium and blood phosphorus, and effectively improve the strength, thickness and weight of eggshell, so as to improve the eggshell quality of eggs produced by laying hens.The application can improve the calcium and phosphorus absorption capacity of laying hens, maintain the balance of calcium and phosphorus metabolism, and has low energy consumption, green energy-saving and environment-friendly advantages.

Interoception is the mechanism by which an individual is informed about the status of its own body. When interoception becomes dysfunctional, it turns into a deleterious event for the health status of an individual. The use of calcitonin gene-related peptide (CGRP) receptor antagonists (gepants) for the treatment and 70 prevention of interoception disorders is described.

The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms and / or headaches (e.g., migraine, cluster headache, and tension headache) by administering an anti-CGRP antagonist antibody. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.

The present disclosure related to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity, and / or dyslipidemia. The disclosure relates to compounds that agonize both the calcitonin and amylin receptors and can lower food intake, body weight, glucose and / or triglycerides, so can be used to treat diabetes, obesity and / or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.

The present invention provides a recombinant protein of monkey procalcitonin, a monoclonal antibody thereof, and a preparation method and application thereof. The amino acid sequence of the recombinant protein of monkey procalcitonin is shown as SEQ ID No.1, and the nucleotide sequence encoding the recombinant protein is shown as SEQ ID No.2. By optimizing the antigen peptide sequence and expression vector, the high-efficiency and soluble expression of monkey procalcitonin in Escherichia coli is achieved. A murine monoclonal antibody specifically binding to monkey procalcitonin is screened based on the recombinant protein of monkey procalcitonin, and a pair of monoclonal antibodies that can be paired is screened using the above murine monoclonal antibody. Further, a double-antibody sandwich immuno-ELISA detection method or kit for the recombinant protein of monkey procalcitonin is constructed based on the pair of monoclonal antibody combinations, which has high detection sensitivity and can be well applied to the detection of monkey serum.

The invention relates to a calcitonin luminescence detection kit and a detection method and application thereof. Specifically, the invention provides the high-sensitivity calcitonin luminescence detection kit, the high-sensitivity calcitonin luminescence detection kit comprises a first reagent and a second reagent, and the first reagent comprises magnetic beads connected with first protein; the second reagent comprises alkaline phosphatase connected with the second protein. The kit improves the detection accuracy and the sample coincidence rate.

The present disclosure provides compounds for modulating calcitonin receptor and / or amylin receptor activity, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating a calcitonin receptor and / or amylin receptor associated disease or disorder.

The application provides a photochemical chemiluminescence detection reagent and a preparation method thereof, and a procalcitonin detection method. The photochemical chemiluminescence detection reagent comprises acceptor microspheres and donor microspheres; wherein the acceptor microspheres are carboxyl-modified acceptor microspheres, and the carboxyl is activated by sulfo-NHS / EDC and coupled with a procalcitonin antibody; and the donor microspheres are carboxyl-modified donor microspheres, and the carboxyl is activated by sulfo-NHS / EDC and coupled with a procalcitonin antibody. The photochemical chemiluminescence detection reagent has higher stability in various environments, can more accurately combine with target molecules, realizes more efficient detection and recognition, and enables the microspheres to more accurately capture and fix the target molecules, so as to perform subsequent luminescence reaction. The detection method has high sensitivity and a wide range, can be used as a detection reagent for diagnosing and identifying infectious diseases of individuals, and has application value.

The present invention discloses an anti-procalcitonin antibody or a reagent and kit for detecting procalcitonin, relating to the field of antibodies. The anti-procalcitonin antibody disclosed in the present invention comprises a heavy chain complementary determining region and a light chain complementary determining region. The antibody provides an important source of raw materials for the detection of procalcitonin and has good affinity or activity.

Methods for treating cluster headache are provided comprising the administration of an anti-CGRP antagonist antibody to a patient in need thereof.

Methods of systemically treating neuropathic pain in a spinal cord injured patient by administering a calcitonin gene-related peptide (CGRP) inhibitor are provided. In some variations, pain-producing tissues correlated with sympathetically mediated central neuropathic pain in spinal cord injured (SCI) patients, were acquired.

The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapeutic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents.

The present disclosure provides compounds for modulating calcitonin receptor and / or amylin receptor activity, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating a calcitonin receptor and / or amylin receptor associated disease or disorder.

Provided are an antibody specifically binding to CGRP or an antigen-binding fragment thereof, and a composition comprising same. Also provided are a nucleic acid molecule encoding the antibody or the antigen-binding fragment thereof, a vector and a host cell for expressing the antibody or the antigen-binding fragment thereof, and therapeutic and diagnostic methods and use of the antibody or the antigen-binding fragment thereof.

Interoception is the mechanism by which an individual obtains information about his or her own bodily state. When interoception is dysfunctional, it turns into a detrimental event for the individual's well-being. The use of calcitonin gene-related peptide (CGRP) receptor antagonists (gepants) for the treatment and prevention of interoceptive disorders has been described.

The invention provides a conjugate comprising a peptide that binds to the Calcitonin Gene-Related Peptide Receptor that is linked to a therapeutic or a detectable radionuclide. The conjugates are useful for imaging the Calcitonin Gene-Related Peptide Receptor and for treating diseases wherein the activity of the Calcitonin Gene-Related Peptide Receptor is implicated.

According to this invention, there is provided an automated sample preparation system implemented within a disposable cartridge. The system utilizes finger prick blood or venous blood as an input sample and performs various sample processing steps, including fluidic metering, fluidic routing, and reagent storage with an integrated biosensor. The architecture, of this system, enables efficient and accurate testing of blood parameters, hematology parameters such as CBC, CD4-T cells count, but not limited to, Complete Blood Cell Count (CBC) and measurement of biomarkers such as Troponin, IL-6, Procalcitonin, but not limited to, CRP, Procalcitonin, and IL-6 through ELISA and is flexible to implement other electrochemistry techniques.